[
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT)’s Libre Linked to Fewer Heart Hospitalizations in Diabetes",
    "summary": "Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a notable decrease in hospitalizations for heart-related complications among people with diabetes. For the first time, the data demonstrate that CGM technology can reduce the severity of cardiovascular […]",
    "url": "https://finnhub.io/api/news?id=0558c22fe9c02671af3955f7a2f36b71d296f8e6221dd24546522bf1cf2d5806",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747597796,
      "headline": "Abbott Laboratories (ABT)’s Libre Linked to Fewer Heart Hospitalizations in Diabetes",
      "id": 134577272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a notable decrease in hospitalizations for heart-related complications among people with diabetes. For the first time, the data demonstrate that CGM technology can reduce the severity of cardiovascular […]",
      "url": "https://finnhub.io/api/news?id=0558c22fe9c02671af3955f7a2f36b71d296f8e6221dd24546522bf1cf2d5806"
    }
  }
]